Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-TPP1
- Development stage
- Preclinical
- Lead developer
- North Sichuan Medical College
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
shRNA-TPP1 is a short hairpin RNA (shRNA) designed to silence the expression of TPP1 (also known as ACD), a key component of the telomere shelterin complex. TPP1 is essential for protecting telomere ends and maintaining genomic stability by recruiting telomerase to telomeres. In esophageal squamous cell carcinoma (ESCC), TPP1 is frequently overexpressed and associated with tumor progression and metastasis. By utilizing RNA interference (RNAi), shRNA-TPP1 reduces TPP1 mRNA and protein levels, which has been shown in preclinical models to suppress ESCC cell proliferation, migration, and invasion. This asset is primarily used as a research tool to investigate the role of telomere maintenance in oncogenesis and as a potential therapeutic strategy for TPP1-overexpressing malignancies.
- Other names
- shRNA targeting TPP1TPP1 shRNATPP-1 shRNATPP 1 shRNA
02
Targets
Tripeptidyl-peptidase 1 (TPP1) mRNATPP1 (Tripeptidyl peptidase 1)
Beyond the preview
Go deeper on shRNA-TPP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shRNA-TPP1.